OakChart

Inhibikase Therapeutics Inc

IKTHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

1.63+0.08 (5.16%)
2026-11-12 03:55 CET
Market cap
227.44 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-69.17 USD m
Free cash flow, TTM
-49.37 USD m
EPS diluted, TTM
-0.41
P/E
-
Compare

Price

IKT against its 20, 50 and 200-day averages
2050200beatearnings
1.502.002.502.0M4.1MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26IKTclose 1.6320-day 1.6050-day 1.94200-day 1.931.6352w high52w low

37.5% under the 52-week high of 2.61 on 3 Sep 2026. 52-week low 1.40 on 3 Dec 2025. Last 15 sessions, 20.6% high to low

Volume 0.74× normal · the line is the 50-bar volume average

Profile

IKT
52-week range, 19% of the way up
1.402.61

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in development of protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. It also focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. The company was founded by Milton H. Werner in September 2008 and is headquartered in Wilmington, DE.

IndexRUT
Employees35
IPODec 23, 2020
Beta0.94
ATR, 14d0.12
Rel volume0.74
Short float17.93%
Insider own22.35%
Inst own74.14%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap227.44M
Enterprise Value34.12M
Income-69.17M
Sales0.00M
Book/sh1.35
Cash/sh1.39
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees35
IPODec 23, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B1.21
P/C1.18
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio15.34
Current Ratio15.34
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-0.41
EPS next Y-0.46
EPS next Q-0.11
EPS this Y14.04%
EPS next Y-9.89%
EPS next 5Y5.06%
EPS past 3/5Y51.48% 22.00%
Sales past 3/5Y- -
EPS Y/Y TTM28.48%
Sales Y/Y TTM-100.00%
EPS Q/Q21.58%
Sales Q/Q-
EarningsNov 10 AMC
EPS/Sales Surpr.9.99% -

Ownership

Insider Own22.35%
Insider Trans0.00%
Inst Own74.14%
Inst Trans12.99%
ROA-49.17%
ROE-52.87%
ROIC-36.64%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA201.78%
SMA50-15.76%
SMA200-15.57%
Trades-

Technical

Shs Outstand140.27M
Shs Float108.35M
Short Float17.93%
Short Ratio34.56
Short Interest19.43M
52W High2.61 -37.55%
52W Low1.40 16.43%
Volatility8.77% 7.61%
ATR (14)0.12
RSI (14)46.77
Beta0.94
Rel Volume0.74
Avg Volume562.19K
Volume413,437

Performance

Perf Week4.15%
Perf Month-7.39%
Perf Quarter-32.37%
Perf Half Y-14.21%
Perf YTD-20.49%
Perf Year-0.61%
Perf 3Y63.00%
Perf 5Y-86.62%
Perf 10Y-
Recom1.22
Target Price5.28
Prev Close1.55
Price1.63
Change %5.16%

Analyst ratings

latest 7 of 7
DateActionAnalystRating changeTargetImplied
Oct 13, 2026InitiatedCChardan Capital MarketsNeutral$1.50-8.0%
Jun 10, 2026InitiatedOOppenheimerOutperform$5+206.7%
Mar 04, 2026InitiatedLLadenburg ThalmannBuy$4+145.4%
Jan 21, 2026InitiatedBBofA SecuritiesBuy$6+268.1%
Dec 26, 2025InitiatedHH.C. WainwrightBuy$8+390.8%
Dec 11, 2025InitiatedCCantor FitzgeraldOverweight$4+145.4%
Feb 12, 2025DowngradeHH.C. WainwrightBuy → Neutral

Peers

Mkt cap
TickerCompanyMkt cap
GOSSGossamer Bio Inc71.44M
INSMInsmed Inc26.49B
TENXTenax Therapeutics Inc76.96M
LQDALiquidia Corp4.94B
MNKDMannkind Corp1.35B
KROSKeros Therapeutics Inc187.22M
UTHRUnited Therapeutics Corp25.37B
VCREVicore Pharma Holding AB ADR318.49M
PLRXPliant Therapeutics Inc48.15M
MRKMerck & Co Inc362.83B

Insider trading

2 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
BERMAN DENNIS NDirectorJul 30 '26Option Exercise1.2621,85427,53621,854Jul 31 04:05 PM
Sands Capital Life Sciences Pu10% OwnerNov 21 '25Buy1.452,068,9652,999,99913,018,965Nov 24 03:47 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWCiShares Micro-Cap ETFAUM: 1.22B
VTWVVanguard Russell 2000 Value Index ETFAUM: 1.29B
SBIOALPS Medical Breakthroughs ETFAUM: 192.65M
AVSCAvantis U.S Small Cap Equity ETFAUM: 3.23B
RSSLGlobal X Russell 2000 ETFAUM: 1.43B

News

latest 14 of 200
  • Inhibikase Therapeutics Announces Third Quarter 2026 Financial Results and Highlights Recent Activity (GlobeNewswire) -7.74% +5.16%
  • Inhibikase Therapeutics Announces Participation in Upcoming Investor Conferences During November 2026 (GlobeNewswire)
  • Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors (GlobeNewswire)
  • Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity (GlobeNewswire)
  • Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH (GlobeNewswire) +7.37%
  • Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility (GlobeNewswire) +5.10%
  • Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity (GlobeNewswire) -5.42%
  • Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension (GlobeNewswire)
  • Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity (GlobeNewswire)
  • Bank of America Predicts Up to 240% Jump for These 2 Strong Buy Stocks (TipRanks)
  • Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-10-0.100-0.111-0.1250.000.008
2026Q22026-08-11-0.110-0.108-0.1120.000.008
2026Q12026-05-12-0.100-0.108-0.0950.000.006
2025Q42026-03-26-0.100-0.103-0.0970.000.007
2025Q32025-11-14-0.130-0.130-0.1330.00-2
2025Q22025-08-14-0.110-0.080-0.1100.00-2
2025Q12025-05-14-0.150-0.100-0.1530.000.001
2024Q42025-03-270.880-0.087-0.1750.000.003
2024Q32024-11-14-0.650-0.480-0.6510.000.003
2024Q22024-08-14-0.660-0.670-0.6580.000.002
2024Q12024-05-16-0.730-0.790-0.7330.000.001
2023Q42024-03-27-0.640-0.850-0.6750.000.002
2023Q32023-11-14-0.860-1.120-0.8600.080.001
2023Q22023-08-14-1.110-0.920-1.1060.120.001
2023Q12023-05-15-0.960-0.870-0.9770.060.002
2022Q42023-03-31-1.080-1.140-1.0180.050.001

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-2.100--1.7000.70-
2021FY-4.860-4.680-4.8723.103.40
2022FY-4.320-4.440-4.2970.120.10
2023FY-3.570-2.755-3.5680.260.28
2024FY-1.160-0.903-1.1610.000.00
2025FY-0.490-0.500-0.4900.000.00
2026FY--0.421--0.00
2027FY--0.463--0.00
2028FY--0.419--36.07
2029FY--0.213--163.94
2030FY-0.243--234

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-115010.000.000.00
2026Q4S2026-11-105000.400.002.00
2026Q4S2026-10-265000.400.002.00
2026Q4S2026-10-125100.400.002.00
2026Q4S2026-08-124100.500.002.00
2026Q4S2026-08-083000.500.001.50
2026Q4S2026-06-033010.500.001.50
2026Q4S2026-05-252010.750.001.50
2026Q4S2026-05-222101.000.002.00
2026Q4S2026-05-132000.750.001.50
2026Q4S2026-03-302000.750.001.50
2026Q4S2026-03-271000.000.000.00
2026Q4S2025-12-101001.501.501.50
2026Q4R2026-11-11400-0.13-0.16-0.11

Estimate history

EPS, annual-0.254-1.251-3.327-1.7-4.872-4.297-3.568-1.161-0.491-0.4079
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.651-0.175-0.153-0.11-0.133-0.097-0.095-0.112-0.104
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual2.0614.0411.1230.6983.1010.1230.261000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual1.721.721.721.6754.1934.2056.18669.362131.691140.27
Period201720182019202020212022202320242025MRQ
Shares, quarterly7.46469.36274.34274.51774.808131.691132.033132.033140.27
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.260.123.100.701.124.04
Cost of Goods Sold Incl. D&A0.000.060.030.180.01----
Gross Profit0.00-0.06-0.030.080.12----
Selling, General and Administrative Excl. Other74.6345.8928.5620.1718.2517.182.436.626.16
Research and Development45.5922.3317.1813.6212.0311.360.892.553.65
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-74.63-45.95-28.59-20.09-18.13-14.08-1.73-5.50-2.12
Interest Expense0.000.00--0.000.020.030.020.03
Unusual Expense0.276.030.000.000.000.691.090.200.00
Net Income Before Taxes-69.17-48.26-27.52-19.03-18.05-14.79-2.85-5.72-2.15
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-69.17-48.26-27.52-19.03-18.05-14.79-2.85-5.72-2.15
Net Income From Continuing Operations-69.17-48.26-27.52-19.03-18.05-14.79-2.85-5.72-2.15
Net Income-69.17-48.26-27.52-19.03-18.05-14.79-2.85-5.72-2.15
EPS (Recurring)-0.35-0.45-1.16-3.57-4.30-4.71-1.25-3.25-1.25
EPS (Basic, Before Extraordinaries)-0.41-0.49-1.16-3.57-4.30-4.87-1.70-3.33-1.25
EPS (Diluted)-0.41-0.49-1.16-3.57-4.30-4.87-1.70-3.33-1.25
EBITDA-74.63-45.89-28.56-19.91-18.12-14.08-1.73-5.50-2.12
Non-Operating Income (Expense)5.723.721.071.060.070.000.000.000.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense20.9715.318.140.500.461.530.571.440.64
Price To Sales Ratio---26.00102.128.6399.29--
Gross Margin---31.9094.55----
Operating Margin----7,711.98-14,686.17-454.02-248.13-490.00-52.52
Net Margin----7,304.73-14,625.85-476.88-407.73-509.73-53.27
Shares Outstanding140.27131.6969.366.194.204.191.681.721.72
Market Capitalization227.44227.44218.387.8412.6136.9869.3571.96-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.020.020.010.01
Gross Profit0.000.000.000.00-0.02-0.02-0.01-0.01
Selling, General and Administrative Excl. Other22.2321.0518.2213.1313.2411.1715.7512.92
Research and Development15.0013.3910.846.367.635.2510.507.19
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-22.23-21.05-18.22-13.13-13.26-11.19-15.76-12.93
Interest Expense0.000.000.000.000.000.000.00-
Unusual Expense0.000.00-0.370.64-0.49-0.36-1.160.00
Net Income Before Taxes-20.47-19.59-16.38-12.73-11.93-9.92-13.68-12.13
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-20.47-19.59-16.38-12.73-11.93-9.92-13.68-12.13
Net Income From Continuing Operations-20.47-19.59-16.38-12.73-11.93-9.92-13.68-12.13
Net Income-20.47-19.59-16.38-12.73-11.93-9.92-13.68-12.13
EPS (Recurring)-0.10-0.11-0.10-0.09-0.14-0.11-0.16-0.17
EPS (Basic, Before Extraordinaries)-0.10-0.11-0.10-0.10-0.13-0.11-0.15-0.17
EPS (Diluted)-0.10-0.11-0.10-0.10-0.13-0.11-0.15-0.17
EBITDA-22.23-21.05-18.22-13.13-13.24-11.17-15.75-12.92
Non-Operating Income (Expense)1.761.461.461.040.840.920.920.80
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense5.535.355.564.534.534.212.047.91
Shares Outstanding140.27132.03132.03131.6974.8174.5274.3469.36
Market Capitalization227.44268.03221.82248.60120.72144.97151.90218.38

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments178.7697.5413.2523.0540.7513.950.020.380.02
Short Term Receivables0.000.000.000.040.110.000.000.470.18
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets1.350.910.961.281.610.830.020.400.00
Total Current Assets180.1198.4514.2124.3742.4714.780.041.250.20
Net Property, Plant & Equipment0.000.150.300.570.000.000.000.000.00
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Long-Term Note Receivable--------0.09
Intangible Assets-0.000.000.000.000.000.000.000.00
Other Assets1.100.000.000.000.000.000.001.590.00
Total Assets181.2098.6014.5124.9442.4714.780.042.850.29
Short Term Debt Incl. Current Port. of LT Debt0.000.110.530.150.250.040.100.230.46
Accounts Payable1.160.940.651.151.091.721.000.950.35
Other Current Liabilities7.142.682.262.402.722.963.152.440.91
Total Current Liabilities8.303.733.443.704.054.724.253.621.73
Long Term Debt0.000.000.090.210.000.280.280.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.000.000.00
Total Liabilities8.303.733.533.904.055.004.533.621.73
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity172.9094.8710.9821.0438.429.78-4.49-0.78-1.44
Total Shareholders Equity172.9094.8710.9821.0438.429.78-4.49-0.78-1.44
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity172.9094.8710.9821.0438.429.78-4.49-0.78-1.44
Total Liabilities & Stockholders Equity181.2098.6014.5124.9442.4714.780.042.850.29
Book Value Per Share1.311.371.775.009.165.84-2.61-0.45-0.84
Tangible Book Value Per Share1.311.371.775.009.165.84-2.61-0.45-0.84
Full-Time Employees35168668---
Price to Book Ratio1.21-45.720.450.500.967.09-14.90--
Return on Assets-34.49-48.66-96.49-53.57-51.65-38.43-396.78-137.47-194.64
Return on Equity-36.05-52.00-118.88-60.74-61.35-107.58---
Return on Invested Capital-27.91-29.01-171.93-85.00-38.49-28.31---
Quick Ratio21.7026.374.136.5910.473.130.010.350.11
Current Ratio21.7026.374.136.5910.473.130.010.350.11

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-69.17-48.26-27.52-19.03-18.05-14.79-2.85-5.72-2.15
Depreciation0.000.060.030.180.01----
Other Funds (Non Cash)17.6720.368.140.530.532.252.183.751.35
Funds from Operations-51.51-27.84-19.35-18.32-17.52-12.53-0.66-1.97-0.80
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital2.140.060.200.230.17-1.76-0.461.631.52
Cash from Operating Activities-49.37-27.79-19.15-18.09-17.35-14.30-1.13-0.340.71
Capital Expenditures0.00-0.450.00-0.01-0.240.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments-99.102.51-37.0011.67-15.760.000.000.000.00
Purchase of Investments-221.40-39.09-60.46-29.43-20.730.000.000.000.00
Sale Or Maturity of Investments122.3041.6023.4541.104.960.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.09
Cash from Investing Activities-99.102.05-37.0011.66-16.010.000.000.000.09
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock161.52108.46103.488.410.0441.2114.790.00-0.41
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock161.52108.46103.488.410.0441.2114.790.00-0.41
Proceedsfrom Stock Options-0.020.000.008.410.0041.1414.790.00-0.41
Issuance or Reduction of Debt, Net0.000.000.000.00-0.25-0.040.27-0.02-0.03
Change in Long Term Debt0.000.000.000.00-0.25-0.040.27-0.02-0.03
Issuance of Long Term Debt0.000.000.000.000.000.000.270.000.00
Reduction of Long Term Debt0.000.000.000.00-0.25-0.040.00-0.02-0.03
Net Financing Active Other Cash Flow0.390.000.000.000.00-0.080.000.000.00
Other Financing Activities Uses0.390.000.000.000.00-0.080.000.000.00
Cash from Financing Activities161.91108.46103.488.41-0.2041.0915.06-0.02-0.44
Net Change in Cash13.4382.7347.331.98-33.5626.8013.94-0.360.36
Free Cash Flow-49.37-27.80-19.15-18.10-17.59-14.30-1.13-0.340.71
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments193.32159.02170.37178.7677.3287.67
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets5.413.281.811.350.830.82
Total Current Assets198.73162.30172.18180.1178.1588.49
Net Property, Plant & Equipment0.000.000.000.000.000.06
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets-----0.00
Other Assets3.021.291.161.101.440.31
Total Assets201.75163.59173.33181.2079.5988.85
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.04
Accounts Payable0.950.991.591.160.622.70
Other Current Liabilities12.019.274.127.146.086.06
Total Current Liabilities12.9610.265.718.306.708.80
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities12.9610.265.718.306.708.80
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity188.80153.33167.62172.9072.9080.05
Total Shareholders Equity188.80153.33167.62172.9072.9080.05
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity188.80153.33167.62172.9072.9080.05
Total Liabilities & Stockholders Equity201.75163.59173.33181.2079.5988.85
Book Value Per Share1.351.161.271.310.971.07
Tangible Book Value Per Share1.351.161.271.310.971.07
Full-Time Employees---35--
Price to Book Ratio1.211.601.282.101.511.69
Return on Assets-49.17-48.04-38.09-34.49-113.51-84.98
Return on Equity-52.87-51.96-40.23-36.05-131.71-97.49
Return on Invested Capital-10.84-12.78-9.77-7.37-16.37-12.39
Quick Ratio15.3415.8230.1421.7011.6710.06
Current Ratio15.3415.8230.1421.7011.6710.06

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-20.47-19.59-16.38-12.73-11.93-9.92
Depreciation0.000.000.000.000.020.02
Other Funds (Non Cash)4.294.194.374.813.463.85
Funds from Operations-16.17-15.40-12.01-7.93-8.44-6.04
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-1.182.96-0.050.41-2.150.47
Cash from Operating Activities-17.35-12.44-12.06-7.52-10.59-5.57
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-12.61-5.91-80.48-0.10-28.759.84
Purchase of Investments-75.69-55.03-90.58-0.10-39.000.00
Sale Or Maturity of Investments63.0849.1210.100.0010.259.84
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-12.61-5.91-80.48-0.10-28.759.84
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock50.46-0.012.90108.180.250.03
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock50.46-0.012.90108.180.250.03
Proceedsfrom Stock Options-2.90-0.012.900.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.39-0.390.00
Other Financing Activities Uses0.000.000.000.39-0.390.00
Cash from Financing Activities50.46-0.012.90108.57-0.130.03
Net Change in Cash20.49-18.37-89.65100.95-39.474.30
Free Cash Flow-17.35-12.44-12.06-7.52-10.59-5.57

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3017.93%19.4M108.4M572.03K
2026-10-1518.11%19.6M108.4M617.00K
2026-09-3017.93%19.4M108.4M687.47K
2026-09-1517.09%18.5M108.4M751.91K
2026-08-3117.99%19.5M108.4M774.41K
2026-08-1418.45%19.7M106.6M838.70K
2026-07-3119.23%19.1M99.5M852.03K
2026-07-1518.35%18.3M99.5M879.41K
2026-06-3019.51%19.4M99.5M849.46K
2026-06-1518.98%18.9M99.5M1.04M
2026-05-2918.60%18.5M99.5M1.17M
2026-05-1517.77%17.7M99.5M1.94M
2026-04-3017.47%18.0M102.9M1.99M
2026-04-1517.28%17.8M102.9M1.91M
2026-03-3117.33%17.3M99.6M1.84M
2026-03-1317.53%16.0M91.5M1.60M
2026-02-2717.54%16.0M91.5M1.41M
2026-02-1311.52%10.5M91.5M604.21K
2026-01-308.92%8.8M99.1M487.86K
2026-01-157.67%7.6M99.1M416.43K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-108-KCurrent report2026-11-10SEC
2026-10-214Statement of changes in beneficial ownership of securities2026-10-19SEC
2026-10-213Initial statement of beneficial ownership of securities2026-10-19SEC
2026-10-208-KCurrent report2026-10-19SEC
2026-09-088-KCurrent report2026-09-08SEC
2026-08-268-KCurrent report2026-08-21SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-11S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-118-KCurrent report2026-08-11SEC
2026-07-31SCHEDULE 13G/ASEC
2026-07-314Statement of changes in beneficial ownership of securities2026-07-29SEC
2026-07-314Statement of changes in beneficial ownership of securities2026-07-30SEC
2026-07-298-KCurrent report2026-07-29SEC
2026-07-28SCHEDULE 13GSEC
2026-07-238-KCurrent report2026-07-23SEC
2026-07-17SCHEDULE 13GSEC
2026-07-173Initial statement of beneficial ownership of securities2026-07-10SEC
2026-07-148-KCurrent report2026-07-14SEC
2026-06-304Statement of changes in beneficial ownership of securities2026-06-26SEC
2026-06-304Statement of changes in beneficial ownership of securities2026-06-26SEC
2026-06-304Statement of changes in beneficial ownership of securities2026-06-26SEC
2026-06-304Statement of changes in beneficial ownership of securities2026-06-26SEC
2026-06-304Statement of changes in beneficial ownership of securities2026-06-26SEC
2026-06-304Statement of changes in beneficial ownership of securities2026-06-26SEC
2026-06-298-KCurrent report2026-06-26SEC
2026-05-15SCHEDULE 13G/ASEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-113.00M100

Institutional holders

Manager% owned
Sands Capital Alternatives, LLC9.86%
Soleus Capital Management, L.P.8.24%
Trails Edge Capital Partners, LP6.86%
Fairmount Funds Management LLC6.53%
BlackRock, Inc.5.88%
Kalehua Capital Management LLC5.79%
ADAR1 Capital Management, LLC5.59%
Blackstone Inc.4.50%
Siren, L.L.C.4.43%
Nantahala Capital Management, LLC4.09%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.85%
iShares Russell 2000 ETF2.28%
Fidelity Small Cap Index Fund1.00%
iShares Russell 2000 Value ETF0.84%
VANGUARD EXTENDED MARKET INDEX FUND0.80%
VANGUARD RUSSELL 2000 INDEX FUND0.50%
iShares Micro-Cap ETF0.31%
Fidelity Extended Market Index Fund0.31%
Schwab Small-Cap Index Fund0.22%
Master Small Cap Index Series0.18%

OakChart. IKT. Cached 15 minutes.